Poulos Christine, Reed Johnson F, Krishnarajah Girishanthy, Anonychuk Andrea, Misurski Derek
RTI Health Solutions, Research Triangle Park, NC, USA.
RTI Health Solutions, Research Triangle Park, NC, USA.
Value Health. 2015 Jan;18(1):67-77. doi: 10.1016/j.jval.2014.10.010.
Meningococcal disease is rare but can cause death or disabilities. Although the Advisory Committee on Immunization Practices has recommended meningococcal vaccination for at-risk children aged 9 through 23 months, it has not endorsed universal vaccination. Health insurance payments for the vaccination of children who are not at risk are likely to be limited. Use of infant meningococcal vaccines by these families will thus depend on the preferences of physicians who might recommend vaccination to parents, as well as parents' preferences.
To quantify pediatricians' preferences for specific features of hypothetical infant meningococcal vaccines.
A sample of pediatricians (n = 216) completed a Web-enabled, discrete choice experiment survey in which respondents chose between pairs of hypothetical vaccines in a series of trade-off questions. The questions described vaccines with six attributes. A random-parameters logit regression model was used to estimate the relative importance weights physicians place on vaccine features. These weights were used to calculate the predicted probability that a physician chooses hypothetical vaccines with given characteristics.
Pediatricians' choices indicated that increases in vaccine effectiveness were among the most important factors in their vaccine recommendations, followed by increases in the number of injections. The age at which protection begins and the number of additional office visits were less important. Whether a booster was required after 5 years was the least important factor in vaccine recommendations. The results suggest that virtually all (99.9%) physicians in the sample would recommend a vaccine even with the least-preferred features rather than no infant meningococcal vaccine.
Physicians' responses indicate a strong preference for infant meningococcal vaccination.
脑膜炎球菌病虽罕见，但可导致死亡或残疾。尽管免疫实践咨询委员会已建议对9至23个月大的高危儿童接种脑膜炎球菌疫苗，但尚未批准普遍接种。为无风险儿童接种疫苗的医疗保险支付可能有限。因此，这些家庭使用婴儿脑膜炎球菌疫苗将取决于可能向家长推荐接种疫苗的医生的偏好以及家长的偏好。
量化儿科医生对假设的婴儿脑膜炎球菌疫苗特定特征的偏好。
一组儿科医生（n = 216）完成了一项基于网络的离散选择实验调查，在一系列权衡问题中，受访者在成对的假设疫苗之间进行选择。问题描述了具有六个属性的疫苗。使用随机参数logit回归模型来估计医生对疫苗特征赋予的相对重要性权重。这些权重用于计算医生选择具有给定特征的假设疫苗的预测概率。
儿科医生的选择表明，疫苗有效性的提高是他们推荐疫苗时最重要的因素之一，其次是注射次数的增加。开始提供保护的年龄和额外门诊就诊次数的重要性较低。5年后是否需要加强免疫是疫苗推荐中最不重要的因素。结果表明，样本中几乎所有（99.9%）的医生都会推荐一种即使具有最不喜欢特征的疫苗，而不是不接种婴儿脑膜炎球菌疫苗。
医生的回答表明对婴儿脑膜炎球菌疫苗有强烈的偏好。
